ES2113879T3 - Analogos de glp-1 utiles para el tratamiento de diabetes. - Google Patents

Analogos de glp-1 utiles para el tratamiento de diabetes.

Info

Publication number
ES2113879T3
ES2113879T3 ES91903738T ES91903738T ES2113879T3 ES 2113879 T3 ES2113879 T3 ES 2113879T3 ES 91903738 T ES91903738 T ES 91903738T ES 91903738 T ES91903738 T ES 91903738T ES 2113879 T3 ES2113879 T3 ES 2113879T3
Authority
ES
Spain
Prior art keywords
analogs
glp
amino acid
acid substitutions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91903738T
Other languages
English (en)
Spanish (es)
Inventor
Douglas I Buckley
Joel F Habener
Joanne B Mallory
Svetlana Mojsov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2113879T3 publication Critical patent/ES2113879T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ES91903738T 1990-01-24 1991-01-24 Analogos de glp-1 utiles para el tratamiento de diabetes. Expired - Lifetime ES2113879T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46873690A 1990-01-24 1990-01-24
PCT/US1991/000500 WO1991011457A1 (en) 1990-01-24 1991-01-24 Glp-1 analogs useful for diabetes treatment

Publications (1)

Publication Number Publication Date
ES2113879T3 true ES2113879T3 (es) 1998-05-16

Family

ID=23861028

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91903738T Expired - Lifetime ES2113879T3 (es) 1990-01-24 1991-01-24 Analogos de glp-1 utiles para el tratamiento de diabetes.

Country Status (8)

Country Link
EP (1) EP0512042B1 (enExample)
JP (5) JP3262329B2 (enExample)
AT (1) ATE164852T1 (enExample)
CA (1) CA2073856C (enExample)
DE (1) DE69129226T2 (enExample)
DK (1) DK0512042T3 (enExample)
ES (1) ES2113879T3 (enExample)
WO (1) WO1991011457A1 (enExample)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
USRE37302E1 (en) * 1992-03-19 2001-07-31 Novo Nordisk A/S Peptide
BR9306551A (pt) * 1992-06-15 1998-09-15 Pfizer Derivados de peptídeo do tipo glucagona e de insulinotropina
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (en) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK144093D0 (enExample) * 1993-12-23 1993-12-23 Novo Nordisk As
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
AU5685296A (en) * 1995-05-17 1996-11-29 Novo Nordisk A/S Immunoassay for glucagon like protein 1 (glp-1) in plasma
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP1566180A3 (en) * 1996-08-30 2007-08-08 Eli Lilly & Company Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
AU4112497A (en) * 1996-08-30 1998-03-19 Novo Nordisk A/S Glp-2 derivatives
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
ES2222613T3 (es) * 1997-09-12 2005-02-01 Pharis Biotec Gmbh Composicion para la terapia de diabetes mellitus y de la obesidad.
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU1617399A (en) * 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
EP1520582A3 (en) 1998-02-02 2009-07-01 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1061946B1 (en) * 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPH11328947A (ja) 1998-05-18 1999-11-30 Nec Corp 大規模ｆｉｆｏ回路
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
EP1666054A1 (en) 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
JP2002524514A (ja) 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
US6461834B1 (en) 1998-11-06 2002-10-08 Bionebraska, Inc. Clostripain catalyzed amidation of peptides
PL205713B1 (pl) * 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
CN1495198A (zh) * 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
AR021576A1 (es) * 1998-12-07 2002-07-24 Ipsen Pharma Sas Analogos del peptido 1-similar al glucagon, uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen.
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
SI1140148T1 (sl) 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
ATE509028T1 (de) 1999-03-15 2011-05-15 Novo Nordisk As Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1180121B9 (en) 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US7229793B1 (en) * 1999-11-19 2007-06-12 Shire Human Genetic Therapies, Inc. Constructs and cells for production of small peptides
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
AU6479101A (en) 2000-06-16 2002-01-02 Lilly Co Eli Glucagon-like peptide-1 analogs
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
ATE416784T1 (de) 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
NZ534877A (en) 2002-02-28 2006-05-26 Prosidion Ltd Glutaminyl based DPIV inhibitors
MXPA04012497A (es) 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
CA2497794A1 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
EP1543030A2 (en) 2002-09-25 2005-06-22 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
CA2741545A1 (en) 2003-03-28 2004-10-14 National Institute Of Agrobiological Sciences Process for producing plant storage organ with high production of recombinant glp-1 and novel recombinant glp-1
ATE462432T1 (de) 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
EP1961416B1 (en) 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
EP1506967B1 (en) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004266757A1 (en) 2003-08-21 2005-03-03 Novo Nordisk A/S Separation of polypeptides comprising a racemized amino acid
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR20120007079A (ko) 2003-10-15 2012-01-19 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
CA2551039C (en) 2003-12-16 2013-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogues of glp-1
WO2005058252A2 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
BRPI0506694A (pt) 2004-01-08 2007-05-02 Theratechnologies Inc análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
BRPI0507594A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc polipetìdeos hìbridos com propriedades selecionáveis
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
US8946149B2 (en) 2005-04-11 2015-02-03 Amylin Pharmaceuticals, Llc Use of exendin and analogs thereof to delay or prevent cardiac remodeling
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
PT1767545E (pt) 2005-09-22 2010-02-05 Biocompatibles Uk Ltd Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
WO2007051987A1 (en) * 2005-11-01 2007-05-10 Activotec Spp Limited Insulinotropic compounds and uses thereof
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
JPWO2007063907A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
RU2008147398A (ru) * 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
RU2350324C1 (ru) * 2007-08-02 2009-03-27 Закрытое акционерное общество "Биологические исследования и системы" Способ лечения сахарного диабета 2 типа, осложненного полиневропатией
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
WO2010066734A1 (en) 2008-12-08 2010-06-17 Novo Nordisk A/S Counter current purification of polypeptides
PL2373681T3 (pl) * 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
TW201100104A (en) 2009-03-27 2011-01-01 Glaxo Group Ltd Drug fusions and conjugates
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
JP5659224B2 (ja) 2009-05-15 2015-01-28 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリールピリジン
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
ES2582395T3 (es) 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
CN102712589B (zh) 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102666535B (zh) 2009-11-30 2015-02-25 诺华股份有限公司 作为醛固酮合酶抑制剂的咪唑衍生物
CN104327182B (zh) * 2009-12-16 2020-04-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
JP5827218B2 (ja) 2010-04-30 2015-12-02 株式会社三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
WO2011143788A1 (en) 2010-05-17 2011-11-24 Zhejiang Beta Pharma Inc. Novel glucagon like peptide analogs, composition, and method of use
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
CA2821766A1 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
JP5977733B2 (ja) 2011-03-08 2016-08-24 株式会社三和化学研究所 分析方法
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
EA031230B1 (ru) 2011-06-22 2018-12-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты глюкагонового рецептора/glp-1-рецептора
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
WO2013060887A1 (en) * 2011-10-28 2013-05-02 Pharis Biotec Gmbh A polypeptide for the protection against heart ischemia-reperfusion injury
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
EP2788027A2 (en) * 2011-12-09 2014-10-15 Novo Nordisk A/S Glp-1 agonists
HRP20190489T1 (hr) 2012-03-22 2019-05-03 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CA2873536A1 (en) 2012-05-16 2013-11-21 Glaxo Group Limited Polypeptide loaded poca nanoparticles for oral administration
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
UY35548A (es) 2013-05-02 2014-11-28 Glaxosmithkline Ip No 2 Ltd Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
SI3057984T1 (sl) 2013-10-17 2018-10-30 Zealand Pharma A/S Acilirani glukagonski analogi
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
US20190290772A1 (en) * 2016-06-02 2019-09-26 Indiana University Research And Technology Corporation Glucagon-like peptide-1-t3 conjugates
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートおよび使用の方法
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN114958883B (zh) * 2022-04-12 2023-01-31 北京惠之衡生物科技有限公司 一种表达glp-1类似物的重组工程菌及其构建方法
WO2024106505A1 (ja) * 2022-11-16 2024-05-23 株式会社ポル・メド・テック 豚臓器又はその由来物を含む移植材の製造方法
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE110083T1 (de) * 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.

Also Published As

Publication number Publication date
EP0512042B1 (en) 1998-04-08
JP2001151798A (ja) 2001-06-05
DE69129226T2 (de) 1998-07-30
JP2003192698A (ja) 2003-07-09
DE69129226D1 (de) 1998-05-14
CA2073856A1 (en) 1991-07-25
EP0512042A4 (en) 1993-02-17
DK0512042T3 (da) 1998-05-11
WO1991011457A1 (en) 1991-08-08
ATE164852T1 (de) 1998-04-15
CA2073856C (en) 2002-12-03
JP3262329B2 (ja) 2002-03-04
JPH05506427A (ja) 1993-09-22
JP2005132848A (ja) 2005-05-26
EP0512042A1 (en) 1992-11-11
JP2004196825A (ja) 2004-07-15

Similar Documents

Publication Publication Date Title
ES2113879T3 (es) Analogos de glp-1 utiles para el tratamiento de diabetes.
ATE251642T1 (de) Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides
US20240376175A1 (en) Novel GLP-1 Analogues
ES2247676T3 (es) Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
RU2208015C2 (ru) Аналоги гпп-1
RU2353625C2 (ru) Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
JP2005530732A5 (enExample)
ES2359031T3 (es) Composición farmacéutica que comprende un péptido de exendina-4.
ATE458054T1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip
KR960013384A (ko) 글루카곤과 유사한 인슐린지향성 펩티드 유사체, 조성물 및 사용 방법
MXPA01009805A (es) Peptido.
RU2000109305A (ru) ЗАЖИВЛЕНИЕ ПЕРЕЛОМОВ С ПОМОЩЬЮ АНАЛОГОВ ПЕПТИДА, ПОДОБНОГО ПАРАТИРЕОИДНОМУ ГОРМОНУ (РТНrР)
KR950701818A (ko) 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
DK0523330T3 (da) Implanterbare sammensætninger indeholdende et biologisk aktivt protein, peptid eller polypeptid
ATE519782T1 (de) Peptide und ihre verwendung zur behandlung von hiv infektionen
ECSP951557A (es) Analogos composiciones y procedimientos de uso de peptidos insulinotropicos similares al glucagon
DE69707690D1 (de) Neue peptide und nootroper wirkstoff
DK119391A (da) Humaninsulinanaloger
Glu et al. represents corticotropin B whenever the exposure to pepsin is kept within
TH50339B (th) การสมานรอยหักของกระดูกโดยใช้อานาลอกของ PTHrP
TH44085A (th) อะนาลอกของ flint ที่ทนต่อโปรตีเอส
TH26711A (th) " สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "
AR005791A1 (es) Proteina de hormona del crecimiento humano mutante; desoxirribo-nucleotido que la codifica; peptido de dicha proteina; plasmido de expresion deldesoxirribonucleotido; producto generado por las celulas transformadas por el anterior; anticuerpo y medicamento que contiene la proteina o el

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 512042

Country of ref document: ES